Starpharma and Radiopharm Theranostics Partner to Develop Novel Radiotherapy Asset

Small Caps

Sep 30

Starpharma Holdings (ASX: SPL) has entered into a research and option partnership with Radiopharm Theranostics (ASX: RAD) to develop and manufacture a dendrimer drug conjugate incorporating a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2571954633"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571954633\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571954633?lang=en_US&edition=fundamental","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/09/Starpharma-Radiopharm-Theranostics-ASX-RAD-SPL-Develop-Novel-Radiotherapy-Asset.jpg","is_english":true,"pubTime":"2025-09-30 10:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571954633","market":"us","top_or_hot":-1,"title":"Starpharma and Radiopharm Theranostics Partner to Develop Novel Radiotherapy Asset","media":"Small Caps","content":"<div>\n<p>Starpharma Holdings (ASX: SPL) has entered into a research and option partnership with Radiopharm Theranostics (ASX: RAD) to develop and manufacture a dendrimer drug conjugate incorporating a ...</p>\n\n<a href=\"https://smallcaps.com.au/starpharma-radiopharm-theranostics-partner-develop-novel-radiotherapy-asset/\">Source Link</a>\n\n</div>\n","source":"smallcap_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Starpharma and Radiopharm Theranostics Partner to Develop Novel Radiotherapy Asset</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStarpharma and Radiopharm Theranostics Partner to Develop Novel Radiotherapy Asset\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-30 10:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://smallcaps.com.au/starpharma-radiopharm-theranostics-partner-develop-novel-radiotherapy-asset/><strong>Small Caps</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Starpharma Holdings (ASX: SPL) has entered into a research and option partnership with Radiopharm Theranostics (ASX: RAD) to develop and manufacture a dendrimer drug conjugate incorporating a ...</p>\n\n<a href=\"https://smallcaps.com.au/starpharma-radiopharm-theranostics-partner-develop-novel-radiotherapy-asset/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7501","symbol_name":"新冠治疗股","start_time":0,"source_url":"https://smallcaps.com.au/starpharma-radiopharm-theranostics-partner-develop-novel-radiotherapy-asset/","article_id":"2571954633","we_media_id":null,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/09/Starpharma-Radiopharm-Theranostics-ASX-RAD-SPL-Develop-Novel-Radiotherapy-Asset.jpg"],"rights":{"source":"smallcap_stock","url":"https://smallcaps.com.au/starpharma-radiopharm-theranostics-partner-develop-novel-radiotherapy-asset/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2571954633","pubTimestamp":1759198273,"columns":[],"sourceInfo":{"source_id":"smallcap_stock","name":"Small Caps"},"weMediaInfo":null,"summary":"The partnership, which follows six months of preliminary research under Starpharma’s Star Navigator drug development program, will see Radiopharm pay Starpharma a $500,000 for an exclusive option to licence the new asset.Starpharma has spent the past 12 months optimising Star Navigator, while showcasing the unique capabilities of dendrimers at high-profile scientific conferences to generate industry interest and open new avenues for collaboration.“The Star Navigator initiative was launched this year to facilitate partnerships by allowing collaborators to access and evaluate the benefits of our technology within their own research and development programs,” Starpharma chief executive officer Cheryl Maley said.“Our engagement with Radiopharm speaks to the value of our technology and will demonstrate how our DEP platform can help shape the future oftargeted cancer therapies.”She added that the collaboration does not impact the progress of Starpharma’s internal development efforts such as ","collect":0,"end_time":0,"defaultTopTitle":"smallcaps.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7501":"新冠治疗股","SPL.AU":"STARPHARMA HOLDINGS LTD","BK7096":"制药","RAD.AU":"RADIOPHARM THERANOSTICS LTD","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"Starpharma和Radiopharm Theranostics合作开发新型放射治疗资产","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAD.AU":1,"SPL.AU":1},"content_text":"Starpharma Holdings (ASX: SPL) has entered into a research and option partnership with Radiopharm Theranostics (ASX: RAD) to develop and manufacture a dendrimer drug conjugate incorporating a radiopharmaceutical molecule to target certain cancers.\nThe partnership, which follows six months of preliminary research under Starpharma’s Star Navigator drug development program, will see Radiopharm pay Starpharma a $500,000 for an exclusive option to licence the new asset.\nThe work will commence immediately utilising Starpharma’s proprietary dendrimer-enhanced product (DEP) delivery platform and Starpharma will also receive an upfront payment of $2 million and be eligible to receive up to $89m in success-based development, regulatory, and commercial milestones.\nStar Navigator Optimisation\nStarpharma has spent the past 12 months optimising Star Navigator, while showcasing the unique capabilities of dendrimers at high-profile scientific conferences to generate industry interest and open new avenues for collaboration.\n“The Star Navigator initiative was launched this year to facilitate partnerships by allowing collaborators to access and evaluate the benefits of our technology within their own research and development programs,” Starpharma chief executive officer Cheryl Maley said.\n“Our engagement with Radiopharm speaks to the value of our technology and will demonstrate how our DEP platform can help shape the future of targeted cancer therapies.”\nFirst Radiopharmaceutical Partnership\nMs Maley said the company was keen to embark on its first radiopharmaceutical partnership, which is also the first Star Navigator program to advance to a formal research collaboration.\n“This agreement provides external validation of the potential of dendrimers in the fast-evolving area of radiopharmaceutical drug development,” she said.\n“Radiopharmaceuticals are a key area of focus for us and our strategy involves developing high-value, differentiated assets and forming strategic partnerships supported by robust scientific data.”\nShe added that the collaboration does not impact the progress of Starpharma’s internal development efforts such as its HER2-targeted radiotheranostic program, which remains a core priority.\nPromoting Radiopharm’s Research\nRadiopharm’s chief executive officer Riccardo Canevari said the partnership would help promote the company’s research.\n“With the targeted radiotherapeutic sector evolving fast into new mechanism of actions and modalities, we are committed to exploring different and innovative options that have the potential to improve the efficacy and the safety of new radiopharmaceutical vectors,” he said.\n“We are excited by the opportunity to work with the capable team of Starpharma to pursue this important and ambitious goal.”","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}